Background: The coronavirus disease 19 (COVID-19) recently became one of the leading causes death worldwide, similar to cardiovascular (CVD). Coexisting CVD may influence prognosis patients with COVID-19. Aims: We analyzed impact and use drugs on in-hospital course mortality Methods: retrospectively studied data for consecutive admitted our hospital, COVID-19 between March 6th October 15th, 202...

In the Heart Outcomes Prevention Evaluation (HOPE) study, investigators found that ramipril was associated with improved survival as well decreased myocardial infarction (MI) and stroke rates in patients peripheral arterial disease. Nonetheless, their effect on chronic limb-threatening ischemia (CLTI)-specific outcomes is unclear. We aim to assess of angiotensin-converting enzyme inhibitors/ang...

BACKGROUND Heart failure (HF) remains a significant cause of morbidity and mortality. Multiple trials over the past several years have examined the effects of both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in the treatment of left ventricular dysfunction, both acutely after myocardial infarction and in chronic heart failure. Yet, there is still...

PURPOSE Angiotensin-converting-enzyme inhibitors (ACEIs) provide renal protection in patients with type 2 diabetes and microalbuminuria. MATERIAL AND METHODS In the presented study we followed 34 stable, type 2 diabetic patients with persistent albuminuria treated with maximal doses of ACEIs as a part of their anti-hypertensive treatment. Telmisartan--an angiotensin receptor blocker (ARB)--in...

conclusions spironolactone combined with aceis or arbs leads to reduction of proteinuria in chronic kidney disease and therefore reduction of progression of the disease. objectives the study was designed to assess the effects of spironolactone as the aldosterone antagonist combined with acei or arb drugs to reduce proteinuria in chronic kidney disease to prevent its progression. patients and me...

Although angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) belong to a family of therapies that block the renin-angiotensin system and are suggested to improve proteinuria/albuminuria, it is unclear which is more effective. To compare the effects of ACEIs and ARBs on proteinuria in primary hypertension by performing a meta-analysis covering randomized con...

BACKGROUND In contrast to previous studies, recent data questioned the ability of renin-angiotensin-aldosterone system (RAAS) blockers to delay progression of diabetic nephropathy. This study evaluated the effect of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in patients with diabetic nephropathy. METHODS A systematic literature search of MEDLINE/...

BACKGROUND AND OBJECTIVES It is known that angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers (ACEIs and ARBs, respectively) are effective in preventing atrial fibrillation (AF) in high-risk patients. However, it is not known whether ACEIs and ARBs are effective in preventing the recurrence of AF after catheter ablation. SUBJECTS AND METHODS One hundred fifty...

Objective: Many chronic diseases, such as hypertension, diabetes, and coronary heart disease, paving the way for disease to progress unfavorably in Covid-19. Angiotensin-converting enzyme inhibitors (ACEIs) angiotensin-2 receptor blockers (ARBs) can upregulate ACE2 receptors (which SARS-COV-2 uses enter host cell) or protect against infection by limiting effects of Angiotensin 2. This study aim...

Background: We aimed to explore the association of clinical symptoms COVID-19 pneumonia, blood parameters on admission, and anti-hypertensive drugs with in-hospital outcomes, including length hospital intensive care unit (ICU) stay, receiving mechanical ventilation, degree lung injury, death among patients hypertension. Material methods: This retrospective study conducted in newly diagnosed pne...